New investigational drug reduces MDR-TB deaths
Approximately three-quarters of patients who received six months of treatment with delamanid, combined with an optimized background regimen, had favorable outcomes two years later. Approximately half of patients treated for two months or less had a favorable outcome from the treatment, MedPageToday reports.
Mortality in the long-term treatment group was one percent, compared to 8.3 percent among the patients who received a placebo or got a short course of the drug.
The results of the study, which were reported in the European Respiratory Journal, were based on a randomized blinded trial testing two doses of the drug for two months and a six month extension of delamanid treatment. Some patients had between six and eight months of the drug treatment and some had two months or less.
The researchers found little difference between patients with eight months of treatment and six months of treatment. The combination of the two groups resulted in 74.5 percent of favorable outcomes with a 57.3 cure rate, according to MedPageToday.
In the short term group, the favorable outcome rate was 55 percent and the cure rate was 48.5 percent.
The Rockville, Md.-based Otsuka Pharmaceutical Development and Commercialization conducted the study and is developing the drug.